The Quantellect read.As of Nov 19, 2026, 24 active firms cover Boston Scientific Corp: 19 rate it Buy or better, 5 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $48.00 to $100.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $66.55 sits 52% above the current $43.70. The rating mix has stayed broadly stable, with Buy-side ratings easing from 21 to 19 over recent months. On the fundamentals, the Street sees revenue growth near 8% this year and 9% next, consensus EPS building from about $0.74 next quarter toward $3.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy1979%
Neutral521%
Sell00%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$66.55
+52.3% upside
Average target across 20 active firms as of Nov 19, 2026 vs $43.71 current
Highest Target$100.00
Average Target$66.55
Lowest Target$48.00
Detailed analyst forecasts for BSX
Showing 1–25 of 25 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 19 of 24 active firms rate BSX a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BSX EPS & revenue forecast
EPS · NEXT QUARTER
$0.74
Range $0.70 – $0.78 · 16 analysts · -7% YoY
Next period, 16 analysts expect Boston Scientific Corp to earn $0.74 a share (range $0.70 – $0.78), versus $0.80 a year earlier. Full-year consensus is $3.17, growing to $3.13 the year after.
REVENUE · NEXT QUARTER
$5.1B
Range $4.9B – $5.1B · 16 analysts · +7% YoY
Revenue is expected to reach $5.1B (range $4.9B – $5.1B), +7.0% year-over-year. Full-year consensus is $21.0B, rising to $20.9B next year.
Top analysts covering Boston Scientific Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BSX.
#1
Joanne Wuensch
Citigroup · Rank #35
Neutral
$48.00+9.8% to target
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$50.00+14.4% to target
Overall win rate
45%
+ Follow
#3
JB
Jayson Bedford
Raymond James · Rank #191
Buy
$88.00+101.3% to target
Overall win rate
44%
+ Follow
#4
Mike Matson
Needham · Rank #285
Buy
$57.00+30.4% to target
Overall win rate
36%
+ Follow
#5
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
$55.00+25.8% to target
Overall win rate
36%
+ Follow
BSX stock forecast FAQ
What is BSX's average 12-month price target?+
The 20 active firms with a live target average $66.55 for Boston Scientific Corp over the next 12 months, ranging from a $100.00 high to a $48.00 low, as of Nov 19, 2026.
Is BSX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 19 rate it Buy or Strong Buy, 5 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BSX?+
The Street-high target is $100.00 (Jefferies), and the Street-low is $48.00 (Barclays). The average of all 20 active-firm targets is $66.55.
How many active Wall Street firms cover BSX?+
24 active firms have a recognized rating on Boston Scientific Corp as of Nov 19, 2026, and 20 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BSX?+
Among analysts who currently cover BSX, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Neutral with a $48.00 target.
What is Boston Scientific Corp's projected EPS for next quarter?+
The consensus estimate is $0.74 per share (range $0.70 – $0.78) across 16 analysts. Full-year EPS is projected at $3.17, rising to $3.13 the following year.
How much revenue is Boston Scientific Corp expected to report next quarter?+
Consensus revenue is $5.1B (range $4.9B – $5.1B). Full-year revenue is projected at $21.0B, growing to $20.9B next year.
Have analysts been upgrading or downgrading BSX lately?+
As of Nov 19, 2026, 19 of 24 active firms rate BSX a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BSX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.